HealthDay News — For patients who have undergone percutaneous coronary intervention (PCI), routine follow-up coronary angiography (FUCAG) has no long-term clinical benefit, according to a study published online January 1 in JACC: Cardiovascular Interventions.

Hiroki Shiomi, MD, from Kyoto University in Japan, and colleagues examined the long-term clinical impact of routine FUCAG after PCI in a prospective multicenter open-label randomized trial. Participants who underwent PCI were randomly allocated to routine angiographic follow-up (AF), in which they received FUCAG at eight to 12 months after PCI, or clinical follow-up alone (CF). Seven hundred patients were enrolled and randomized to AF (349 patients) or CF (351 patients). 

Related Articles

The researchers found that the cumulative five-year incidence of the primary end point (composite of death, myocardial infarction, stroke, emergency hospitalization for acute coronary syndrome, or hospitalization for heart failure) was 22.4 and 24.7% in the AF and CF groups, respectively (hazard ratio, 0.94; 95% confidence interval, 0.67 to 1.31; P=0.7). Within the first year, any coronary revascularization was performed more frequently in the AF group than the CF group (12.8 versus 3.8%; log-rank P<0.001); over time the difference was attenuated with similar cumulative five-year incidence (19.6 versus 18.1%; log-rank P=0.92).

“Routine FUCAG cannot be recommended as a clinical strategy,” the authors conclude. “However, the present study was underpowered to detect modest benefits (or harm) of routine FUCAG, and larger scale trials (especially in high-risk patients) are warranted to definitively address this issue.”

One author disclosed ties to Boston Scientific Corp.

Full Text